Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997423 · ClinicalTrials.gov registry record
Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
A clinical trial, sponsored by University of Iowa.
- Completed
- Registry status
- 153
- Enrollment target
NCT02997423 is a clinical trial that has completed, run by University of Iowa. The registered enrollment target is 153 participants.
The verdict
NCT02997423 has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- 153 participants
- Enrollment target
Study Summary
This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly diagnosed primary GBM is associated with shortened OS (primary outcome) and PFS (secondary outcome) times.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2016-11-30 |
| Est. Completion | 2022-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02997423
The ClinicalTrials.gov registry entry for NCT02997423 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02997423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02997423 about?
NCT02997423 is a clinical study titled "Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)". This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly diagnosed primary GBM is associated with shortened OS (primary outcome) and PF...
What is the current status of trial NCT02997423?
This trial is currently completed. The enrollment target is 153 participants. The study started on 2016-11-30. Estimated completion is 2022-11-30.
Who is sponsoring clinical trial NCT02997423?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.